Stocksigma LogoStocksigma Logo

Ind-Swift Laboratories Reports Strong Q2FY27 Growth Driven by FDF Platform Scale-Up

Ind-Swift Laboratories reported standalone revenue of ₹242.49 crore for Q2FY27, up 25.18% QoQ, with operating EBITDA increasing 27.04% QoQ to ₹42.33 crore

Ind-Swift Laboratories Reports Strong Q2FY27 Growth Driven by FDF Platform Scale-Up

Ind-Swift Laboratories Ltd · Investor Presentation · 04 Nov 2026, 5:11 pm

Ind-Swift Laboratories Reports Strong Q2FY27 Growth Driven by FDF Platform Scale-Up Ind-Swift Laboratories reported standalone revenue of ₹242.49 crore for Q2FY27, up 25.18% QoQ, with operating EBITDA increasing 27.04% QoQ to ₹42.33 crore (18.02% margin) and PAT reaching ₹31.03 crore. For H1FY27, revenue reached ₹436.20 crore (up 31.83% YoY) and PAT grew 3.3x YoY to ₹55.47 crore. Following its transition to a pure-play Finished Dosage Formulation (FDF) player, the net-debt-free company is funding a ₹250 crore capex via internal accruals, targeting >50% FY27 revenue growth and a medium-term revenue CAGR of 20-25%.

Original exchange filing (PDF)

More announcements from Ind-Swift Laboratories Ltd

All Ind-Swift Laboratories Ltd announcements